Breast Cancer: Patients To Enroll In Clinical Trial 

0
131
pharmacy

Breast Cancer: Patients To Enroll In Clinical Trial 
A woman examining her breast.

 

Prof. Dimitrios Fotiadis, Cardiocare project coordinator, University of Ioannina, Greece, has said that women with breast cancer can be enrolled in a clinical trial to reduce heart damage.

In a statement posted on the European Society of Cardiology (ESC) website on Monday, Fotiadis said that the clinical trial would examine the ability of behavioural and psychological interventions to reduce heart damage from anti-cancer therapies.

According to the World Health Organisation (WHO), breast cancer is a disease in which abnormal breast cells grow out of control and form tumours. WHO says that if the tumours are left unchecked, they can spread throughout the body and become fatal.

READ
Study Says Your Choice of Food Could Influence Cancer Risk

The body also disclosed that breast cancer occurs in every country in the world and caused 685,000 deaths globally in 2020.

Fotiadis said that cardiovascular disease was a devastating complication of anti-cancer treatment that affected physical and mental health of patients. He also stated that breast cancer is the most frequently occurring tumour in the EU, accounting for 13.3 per cent of all new cases in 2020.

“It is estimated that one in 11 women in the EU will develop breast cancer by the age of 74. CARDIOCARE will provide women over the age of 65 with breast cancer, the tools to improve their physical health and to psychologically adapt to the disease,” he said.

READ
Tuberculosis: Foundation Screens 760 Persons in Lagos

Fotiadis said that the five-year EU-funded project aimed to radically change the management of older women with breast cancer.

“A clinical trial evaluating the impact of behavioural and psychological interventions on quality of life, physical and mental wellbeing, as well as the cardiotoxic effects of breast cancer treatment, will be conducted in 750 breast cancer patients at six clinical centres in Europe. All patients in the trial will receive the CARDIOCARE mobile application (app).

“Participants will be randomly allocated to receive the app, incorporating the ePsycHeart and eHealtHeart, or to receive the app with ePsycHeart only ePsycHeart will monitor quality of life, mobility and mental health using a wearable chest band heart rate sensor, smartwatch and questionnaires. eHealtHeart will encourage patients in the intervention group to adopt behaviours including physical activity, healthy diet, games to improve memory and changing the home environment to reduce the risk of falls, he said.

READ
Open Defecation Attracts Seven Lashes, N200 Fine in Kaduna Community

Fotiadis noted that the project would harness the expertise of cardiologists, oncologists, psychologists, molecular biologists, bioinformaticians, computer scientists and biomedical engineers from seven countries across Europe.

NAN

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here